The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Top Cited Papers
Open Access
- 1 December 2005
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 57 (4) , 547-583
- https://doi.org/10.1124/pr.57.4.2
Abstract
The evolution of iron chelators from a range of primordial siderophores and aromatic heterocyclic ligands has lead to the formation of a new generation of potent and efficient iron chelators. For example, various siderophore analogs and synthetic ligands, including ICL670A [4-[3,5-bis-(hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid], 4′-hydroxydesazadesferrithiocin, and Triapine, have been developed from predecessors and illustrate potent iron-mobilizing or antineoplastic activities. This review focuses on the evolution of iron chelators from initial lead compounds through to the development of novel chelating agents, many of which show great potential to be clinically applied in the treatment of iron overload disease and cancer.Keywords
This publication has 229 references indexed in Scilit:
- Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analoguesJBIC Journal of Biological Inorganic Chemistry, 2003
- β-Thalassaemia: emergence of new and improved iron chelators for treatmentThe International Journal of Biochemistry & Cell Biology, 2003
- Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicityAmerican Journal of Hematology, 2003
- Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazine ligands with high iron chelation efficacyJBIC Journal of Biological Inorganic Chemistry, 2001
- The Hexadentate Hydroxypyridinonate TREN‐(Me‐3,2‐HOPO) is a More Orally Active Iron Chelator Than Its Bidentate AnalogueJournal of Pharmaceutical Sciences, 2000
- Novel iron complexes and chelators based on cis,cis-1,3,5-triaminocyclohexane: iron-mediated ligand oxidation and biochemical propertiesJBIC Journal of Biological Inorganic Chemistry, 1998
- The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cellsBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1997
- The Three-dimensional Structure of Mammalian Ribonucleotide Reductase Protein R2 Reveals a More-accessible Iron-radical Site thanEscherichia coliR2Journal of Molecular Biology, 1996
- Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanismBiochemical and Biophysical Research Communications, 1983
- Mobilization of iron from reticulocytesFEBS Letters, 1979